Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

Part of paid clinical trials in Charlotte, North Carolina.

Sponsor
Wake Forest University Health Sciences
Study ID
NCT04822337
Phase
PHASE1/PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This research study is being done to learn if the study drug belantamab mafodotin, in combination with other standard medications, can improve multiple myeloma. This study will also help determine what effects, good and/or bad, this combination of study drugs have on subjects and their cancer, and to evaluate the overall response to this study treatment combination.

Key Dates

Start date
May 19, 2021
Status verified
Apr 2026
Primary completion
Apr 30, 2029
Completion
Nov 30, 2032

Study Design

Enrollment
70 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Phase I
    Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
  • Experimental: Phase II
    Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin

Primary Outcome Measure

Establish Maximum Tolerated Dose (MTD) [ Time Frame: time to complete Cycle 1 (28 days) ]

Locations (2)

FacilityCityStateZIPSite coordinators
Levine Cancer InstituteCharlotteNorth Carolina28204-
Atrium Health Wake Forest Baptist Comprehensive Cancer CenterWinston-SalemNorth Carolina27157-

Find similar trials in Charlotte, NC

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
Levine Cancer Institute· Charlotte, NCAtrium Health Wake Forest Baptist Comprehensive Cancer Center· Winston-Salem, NC

Related Studies